Abbott reveals CE mark approval for XIENCE Xpedition Everolimus Eluting System RTT News 8/20/2012 7:19 AM ET (RTTNews) - Global health care company Abbott (ABT:Quote) Monday announced that its novel XIENCE Xpedition Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease has received CE mark in Europe. Abbott Reveals CE Mark Approval For XIENCE Xpedition Everolimus Eluting ... Abbott Announces CE Mark and European Launch of Next-Generation XIENCE ... |
